The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.
Authors:
- 1 April 1994
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 37 (4) , 389-391
Abstract
The pharmacokinetics of the 5‐HT3 receptor antagonist ondansetron following an 8 mg i.v. dose were investigated in 12 subjects previously phenotyped with debrisoquine. Six subjects were poor metabolisers (debrisoquine metabolic ratios 29‐131) and six were extensive metabolisers (debrisoquine metabolic ratios 0.45‐3.4). There was no significant difference in AUC, Cmax, CL or t1/2 between the poor and extensive metabolisers. It is concluded that ondansetron clearance is not mediated exclusively by cytochrome P‐450 2D6.Keywords
This publication has 8 references indexed in Scilit:
- The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment.British Journal of Clinical Pharmacology, 1993
- Age and gender effects on ondansetron pharmacokinetics: Evaluation of healthy aged volunteersClinical Pharmacology & Therapeutics, 1992
- TropisetronDrugs, 1992
- Determination of Ondansetron in Plasma and Its Pharmacokinetics in the Young and ElderlyJournal of Pharmaceutical Sciences, 1991
- Review of methods and criteria for the evaluation of bioequivalence studiesEuropean Journal of Clinical Pharmacology, 1990
- The metabolism of ondansetron.1989
- Pharmacological and anti-emetic properties of ondansetron.1989
- Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detectionJournal of Chromatography A, 1977